Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects With Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Expressing c-Met Protein Level Above a Defined Cutoff

NCT07821684 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07821684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07821684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects With Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Expressing c-Met Protein Level Above a Defined Cutoff
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 6, 2027
Completion date
April 30, 2031
Enrollment
660 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer